{"corpus_id":32908321,"paper_sha":"a24d535936dd95675ea82df6add04b1d171240ea","doi":"10.1200/JCO.2006.08.2305","arxiv_id":null,"pmid":17242397,"pmcid":null,"mag_id":2142724147,"dblp_id":null,"acl_id":null,"title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.","year":2007,"publication_date":"2007-02-10","venue":"Journal of Clinical Oncology","journal":{"name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pages":"\n          571-8\n        ","volume":"25 5"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Consensus Statement","Journal Article","Practice Guideline"],"s2_fields_of_study":["Medicine"],"reference_count":40,"citation_count":1359,"influential_citation_count":70,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Clinical Trials as Topic","mj":false,"qs":[{"q":"standards","mj":false,"ui":"Q000592"}],"ui":"D002986"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Image Interpretation, Computer-Assisted","mj":false,"ui":"D007090"},{"d":"International Cooperation","mj":false,"ui":"D007391"},{"d":"Lymphoma","mj":false,"qs":[{"q":"diagnostic imaging","mj":true,"ui":"Q000000981"},{"q":"therapy","mj":true,"ui":"Q000628"}],"ui":"D008223"},{"d":"Positron-Emission Tomography","mj":true,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D049268"},{"d":"Radiopharmaceuticals","mj":true,"ui":"D019275"},{"d":"Time Factors","mj":false,"ui":"D013997"},{"d":"Tomography, X-Ray Computed","mj":false,"ui":"D014057"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Radiopharmaceuticals","ui":"D019275","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.08.2305?role=tab","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/a24d535936dd95675ea82df6add04b1d171240ea","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"PURPOSE: To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials. METHODS: An International Harmonization Project (IHP) was convened to discuss standardization of clinical trial parameters in lymphoma. An imaging subcommittee developed consensus recommendations based on published PET literature and the collective expertise of its members in the use of PET in lymphoma. Only recommendations subsequently endorsed by all IHP subcommittees were adopted. RECOMMENDATIONS: PET after completion of therapy should be performed at least 3 weeks, and preferably at 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or chemoradiotherapy. Visual assessment alone is adequate for interpreting PET findings as positive or negative when assessing response after completion of therapy. Mediastinal blood pool activity is recommended as the reference background activity to define PET positivity for a residual mass > or = 2 cm in greatest transverse diameter, regardless of its location. A smaller residual mass or a normal sized lymph node (ie, < or = 1 x 1 cm in diameter) should be considered positive if its activity is above that of the surrounding background. Specific criteria for defining PET positivity in the liver, spleen, lung, and bone marrow are also proposed. Use of attenuation-corrected PET is strongly encouraged. Use of PET for treatment monitoring during a course of therapy should only be done in a clinical trial or as part of a prospective registry.","claims":[{"public_id":"cl_82f7f9ff07f029077517664e568ae5b4","status":"active","text":"A smaller residual mass or a normal-sized lymph node should be considered positive if its activity is above the surrounding background.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_82f7f9ff07f029077517664e568ae5b4"},{"public_id":"cl_04fe3b7b6d6fadeb51cd0abddbac9cc5","status":"active","text":"Attenuation-corrected PET is strongly encouraged, and PET for treatment monitoring during therapy should be limited to a clinical trial or a prospective registry.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_04fe3b7b6d6fadeb51cd0abddbac9cc5"},{"public_id":"cl_f5ecf30f00cd8fd0ce6a2dcc4e19391a","status":"active","text":"Mediastinal blood pool activity is the recommended reference background activity for defining PET positivity in a residual mass of 2 cm or greater in greatest transverse diameter, regardless of location.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f5ecf30f00cd8fd0ce6a2dcc4e19391a"},{"public_id":"cl_b332eecb59e2da6b2d3c55d2690bb35d","status":"active","text":"PET after completion of therapy should be performed at least 3 weeks, preferably 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or chemoradiotherapy.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b332eecb59e2da6b2d3c55d2690bb35d"},{"public_id":"cl_2bf590812285706517d9da9203097856","status":"active","text":"Visual assessment alone is adequate for interpreting PET findings as positive or negative when assessing response after completion of therapy.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2bf590812285706517d9da9203097856"}],"concepts":[{"public_id":"co_0c6e8cb305e7a30297f4c4d0d039dd79","status":"active","name":"residual mass","description":"Remaining mass after therapy that is evaluated for PET positivity.","types":["imaging finding"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0c6e8cb305e7a30297f4c4d0d039dd79"},{"public_id":"co_22f55d2a9d80b74dd012f93768b7bf53","status":"active","name":"surrounding background","description":"Local background activity adjacent to a lesion used for comparison in PET interpretation.","types":["reference background"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_22f55d2a9d80b74dd012f93768b7bf53"},{"public_id":"co_40141bb6b4715d398b089c5e0cd1d893","status":"active","name":"PET findings","description":"Observed signal patterns or uptake on positron emission tomography images.","types":["observation"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_40141bb6b4715d398b089c5e0cd1d893"},{"public_id":"co_42fc7464294a562f313b3640eb786ec5","status":"active","name":"lymphoma","description":"A group of malignancies arising from lymphoid tissue that is the disease context for the recommendations.","types":["disease"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_42fc7464294a562f313b3640eb786ec5"},{"public_id":"co_4daf34c6950ed7ffe11f3bbddceca2f4","status":"active","name":"visual assessment","description":"Qualitative interpretation of PET images without relying on quantitative measures alone.","types":["interpretation method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4daf34c6950ed7ffe11f3bbddceca2f4"},{"public_id":"co_715570fdbf853265a658edbfa39d04c3","status":"active","name":"chemotherapy or chemoimmunotherapy","description":"Drug-based systemic cancer treatment used as a timing reference for post-therapy PET.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_715570fdbf853265a658edbfa39d04c3"},{"public_id":"co_8820b1823b7364068cbd046d6466712f","status":"active","name":"positron emission tomography","description":"An imaging technique that detects radiotracer distribution to assess metabolic or functional activity.","types":["imaging modality"],"aliases":["PET"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8820b1823b7364068cbd046d6466712f"},{"public_id":"co_a1cd4dcba7ad14955e07e6fcd286a81d","status":"active","name":"treatment monitoring","description":"Serial imaging used to track response during an ongoing course of therapy.","types":["monitoring"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a1cd4dcba7ad14955e07e6fcd286a81d"},{"public_id":"co_ab2dd55e680fac2bc19cbea27a1d3f72","status":"active","name":"normal-sized lymph node","description":"A lymph node within normal size limits that may still be considered positive based on PET uptake.","types":["anatomical finding"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ab2dd55e680fac2bc19cbea27a1d3f72"},{"public_id":"co_afe9617273d1d0dbb26e8b22d24d0ee8","status":"active","name":"attenuation-corrected PET","description":"PET imaging processed with attenuation correction to compensate for tissue-related signal loss.","types":["imaging technique"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_afe9617273d1d0dbb26e8b22d24d0ee8"},{"public_id":"co_bdbfcc103fa70da7435c491addd3bcc0","status":"active","name":"mediastinal blood pool activity","description":"Activity in the mediastinal blood pool used as the background reference for PET interpretation.","types":["reference standard"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bdbfcc103fa70da7435c491addd3bcc0"},{"public_id":"co_ca34fdad87ffdffb749068ae59df532a","status":"active","name":"clinical trial or prospective registry","description":"A structured research setting in which interim PET monitoring is recommended.","types":["research setting"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ca34fdad87ffdffb749068ae59df532a"},{"public_id":"co_cc7bc747f1b8a5b7f68447716d266f83","status":"active","name":"response assessment","description":"Evaluation of treatment response using imaging findings after therapy.","types":["clinical assessment"],"aliases":["treatment assessment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cc7bc747f1b8a5b7f68447716d266f83"},{"public_id":"co_ec449d31d3bfb76c5f0813b03feaf3dc","status":"active","name":"PET positivity","description":"A PET scan result interpreted as indicating residual active disease.","types":["diagnostic category"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ec449d31d3bfb76c5f0813b03feaf3dc"},{"public_id":"co_f9cd8d0d63a960764abbfafcc9812f7b","status":"active","name":"radiation or chemoradiotherapy","description":"Radiation treatment alone or combined with chemotherapy, used as a timing reference for post-therapy PET.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f9cd8d0d63a960764abbfafcc9812f7b"}],"external_ids":{"DOI":"10.1200/JCO.2006.08.2305","ArXiv":null,"PubMed":17242397,"PubMedCentral":null,"MAG":2142724147,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.08.2305?role=tab","landing_url":"https://www.semanticscholar.org/paper/a24d535936dd95675ea82df6add04b1d171240ea","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631128,"paper_uid":"614a4ddc-717b-4287-8390-b68f011717b0","canonical_identity":{"paper_id":631128,"paper_uid":"614a4ddc-717b-4287-8390-b68f011717b0","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/32908321"}